These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866 [TBL] [Abstract][Full Text] [Related]
28. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562 [TBL] [Abstract][Full Text] [Related]
29. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957 [TBL] [Abstract][Full Text] [Related]
30. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial. Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026 [TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Taylor MH; Betts CB; Maloney L; Nadler E; Algazi A; Guarino MJ; Nemunaitis J; Jimeno A; Patel P; Munugalavadla V; Tao L; Adkins D; Goldschmidt JH; Cohen EEW; Coussens LM Clin Cancer Res; 2022 Mar; 28(5):903-914. PubMed ID: 34862248 [TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. Cho BC; Braña I; Cirauqui B; Aksoy S; Couture F; Hong RL; Miller WH; Chaves-Conde M; Teixeira M; Leopold L; Munteanu M; Ge JY; Swaby RF; Hughes BGM BMC Cancer; 2024 Jul; 23(Suppl 1):1254. PubMed ID: 39054467 [TBL] [Abstract][Full Text] [Related]
34. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240 [TBL] [Abstract][Full Text] [Related]
35. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363 [TBL] [Abstract][Full Text] [Related]
37. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. Vathiotis IA; Johnson JM; Argiris A Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755 [TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831 [TBL] [Abstract][Full Text] [Related]
39. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis. Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X Front Immunol; 2021; 12():645170. PubMed ID: 33897693 [TBL] [Abstract][Full Text] [Related]
40. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. Antonia SJ; Balmanoukian A; Brahmer J; Ou SI; Hellmann MD; Kim SW; Ahn MJ; Kim DW; Gutierrez M; Liu SV; Schöffski P; Jäger D; Jamal R; Jerusalem G; Lutzky J; Nemunaitis J; Calabrò L; Weiss J; Gadgeel S; Bhosle J; Ascierto PA; Rebelatto MC; Narwal R; Liang M; Xiao F; Antal J; Abdullah S; Angra N; Gupta AK; Khleif SN; Segal NH J Thorac Oncol; 2019 Oct; 14(10):1794-1806. PubMed ID: 31228626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]